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Abstract  
 
Interactions between natural killer (NK) cells and dendritic cells (DC) aid DC 
maturation and promote T cell responses. Here, we have analysed the response of 
human NK cells to tumor cells and we identify a pathway by which NK-DC 
interactions occur. Gene expression profiling of tumor-responsive NK cells identified 
the very rapid induction of TNFSF14 (also known as LIGHT), a cytokine implicated 
in the enhancement of anti-tumor responses.  TNFSF14 protein expression was 
induced by three primary mechanisms of NK cell activation, namely via the 
engagement of CD16, by the synergistic activity of multiple target cell-sensing NK 
cell activation receptors and by the cytokines IL-2 and IL-15. For anti-tumor 
responses, TNFSF14 was preferentially produced by the licensed NK cell population, 
defined by the expression of inhibitory receptors specific for self-MHC class I 
molecules. In contrast, IL-2 and IL-15 treatment induced TNFSF14 production by 
both licensed and unlicensed NK cells, reflecting the ability of pro-inflammatory 
conditions to override the licensing mechanism. Importantly, both tumor and cytokine 
activated NK cells induced DC maturation in a TNFSF14-dependent manner. The 
coupling of TNFSF14 production to tumor-sensing NK cell activation receptors links 
the tumor immune surveillance function of NK cells to DC maturation and adaptive 
immunity. Furthermore, regulation by NK cell licensing helps to safeguard against 
TNFSF14 production in response to healthy tissues. 
 
 
Significance  
As well as having potent cytotoxic activity, natural killer (NK) cells have a regulatory 
role and interactions between NK cells and dendritic cells (DC) aid DC maturation 
and adaptive immunity. However, the mechanisms underpinning NK-DC cross talk 
are poorly defined. We show that tumor cells induce the rapid production of the 
cytokine TNFSF14 (also known as LIGHT) in human NK cells and that these NK 
cells induce DC maturation in a TNFSF14-dependent manner.  The synergistic 
activity of NK cell activation receptors in licensed NK cells couples the release of 
cytotoxic granules to TNFSF14 production. Thus, NK cell activation by tumor cells is 
linked to the initiation of adaptive immunity via TNFSF14-mediated NK-DC cross 
talk. 
\body 
Introduction 
Natural killer (NK) cells play an important role in protecting the host against viral 
infection and cancer. As well as having potent cytotoxic activity, NK cells are 
endowed with immunoregulatory activity (1, 2). For example, NK cell activation 
induces the production of chemokines, such as MIP1-α and IL-8, and pro-
inflammatory cytokines such as interferon (IFN)-γ, granulocyte-macrophage colony 
stimulating factor (GM-CSF) and tumor necrosis factor-α (TNF). These molecules 
regulate the recruitment and activity of numerous immune cell types (1, 2).  
Importantly, NK cells can promote development of T cell responses via NK-DC 
interactions that favour both DC maturation and NK cell activation (3-5), with NK 
cell-derived IFN-γ skewing T cell differentiation towards the Th1 phenotype (6, 7).  
Cytotoxic activity and cytokine production are coupled to signalling pathways 
downstream of a repertoire of activating and inhibitory receptors; signals from 
activating receptors (including NKG2D, DNAM-1, 2B4 and the natural cytotoxicity 
receptors, NKp30, NKp44 and NKp46) compete with those from inhibitory receptors 
(such as KIRs and CD94/NKG2A) to regulate activation. In addition, NK cells 
express CD16, the low affinity receptor for IgG, conferring antibody dependent 
cellular cytotoxicity (ADCC) (8-10). Activation thus coordinates the killing of target 
cells, the induction of inflammation and the promotion of adaptive immunity.!This 
potent cytotoxicity and pro-inflammatory activity must be strictly controlled to 
minimise damage to healthy tissue. Functional competency of unstimulated NK cells 
is achieved via a process termed licensing or education (11-14). This ensures that only 
those NK cells expressing inhibitory receptors for self-MHC class I can respond to 
target cells and NK cells that lack inhibitory receptors for self MHC class I molecules 
are rendered hyporesponsive, preventing them from attacking healthy cells expressing 
normal levels of MHC class I molecules.   
We have analysed the consequences of human NK cell activation by tumor 
cells.  Our results reveal induction of the TNF superfamily member TNFSF14, also 
known as Lymphotoxin-like, exhibits inducible expression, and competes with herpes 
simplex virus glycoprotein D for HVEM, a receptor expressed on T lymphocytes 
(LIGHT)(15). We show that activated NK cells produce TNFSF14 in response to 
different stimuli, that tumor cells induce TNFSF14 production by licensed NK cells 
and that TNFSF14 producing NK cells aid DC maturation during NK-DC cross-talk. 
Results   
Gene expression profiling of tumor-stimulated NK cells identifies induction of a 
putative immunomodulatory pathway. 
Gene expression profiling has provided great insight into NK cell function (16-18). 
NK cells respond very rapidly to target cells and we reasoned that analysing the 
changes in gene expression that occur during the early stages of activation by target 
cells might reveal new features of these responses. 
Activation of NK cells by tumor cells results in the rapid exocytosis of 
cytotoxic granules and the expression and release of cytokines. Granule exocytosis 
exposes the granule membrane protein CD107 on the NK cell surface, allowing NK 
cells that have responded to a tumor target (here termed R-NK) to be separated from 
non-responding (NR-NK) cells using fluorescence activated cell sorting (FACS).  We 
purified human peripheral blood NK cells, co-cultured them (in the absence of 
exogenous cytokines) for four hours with K562 tumor cells and sorted the R-NK and 
NR-NK fractions (Fig. 1A).  We performed gene expression profiling on R-NK and 
NR-NK fractions from two sample sets, one derived from a single healthy donor and 
the other using fractions pooled from three additional healthy donors. Not surprisingly 
given donor variability, more genes were differentially regulated in the pooled sample 
compared to the single donor (1108 genes and 670 genes respectively), but there were 
541 genes that were differentially regulated by a factor of 1.5 or more (P<0.05) in 
both sample sets (Fig. 1B and C and supplementary dataset 1). We focused our 
analysis on genes whose expression was upregulated in the R-NK cells; induction of 
genes encoding TNF (TNFSF2), GM-CSF (CSF2), IFN-γ (IFNG) and CD69 was 
detected in R-NK cells as expected (Fig. 1C).  Quantitative RT-PCR analysis of 
mRNA from R-NK and NR-NK cells confirmed induction of a selection of the genes 
identified by the array analysis.  For example, CSF2 and IFNG were induced by some 
two hundred-fold and fifty-fold respectively in the R-NK cells (Fig. 1B).  In addition, 
several KIR genes and KLRC1 (encoding NKG2A) demonstrated greater expression 
in the R-NK fraction, consistent with the higher level of MHC class I inhibitory 
receptor expression in functionally responsive (educated or licensed) human NK cells 
(12, 19). Manual inspection of genes upregulated in the R-NK fraction revealed many 
molecules associated with an immune activation phenotype, including cell surface 
receptors, signalling components and transcription factors, as well as genes associated 
with NK cell effector functions (Fig. 1C and supplementary table 1). As well as TNF 
itself, the R-NK fraction demonstrated increased expression of several TNF 
superfamily (TNFSF) and TNF receptor superfamily (TNFRSF) members. In 
particular, we identified four molecules from the same immunoregulatory network; 
the immunoglobulin superfamily molecule CD160 and the TNF superfamily 
molecules TNFSF14 (LIGHT), TNFSF15 (also known as TNF-like Ligand 1A; 
TL1A) and TNFSF6 (Fas Ligand; FasL).  These genes encode cell surface molecules 
involved in a complex regulatory network involving both cis and trans receptor-
ligand interactions that regulate immune activation events in other cell types (20, 21) 
(Fig. 1D). Both CD160 and TNFSF14 are ligands of TNF receptor superfamily 
molecule TNFRSF14, also known as Herpesvirus entry mediator (HVEM) (15, 22). 
Like other TNFSF receptors, HVEM signals via TNF Receptor Associated Factors 
(TRAFs) to induce NF-κB activity (23, 24).  Furthermore, TNFSF14, TNFSF15 and 
TNFSF6 activity are all antagonised by TNFSFR6B (Decoy Receptor 3; DcR3) (25). 
The potential that tumor cells might induce NK cell expression of molecules within 
this network prompted us to explore the regulation and consequences of their 
expression in more detail. 
 
NK cells rapidly express cell surface TNFSF14 in response to target cell 
stimulation  
We analysed whether tumor-mediated induction of gene expression was mirrored by 
expression of the corresponding proteins.  The K562 tumor cell line induced the 
expression of CD69, TNFRSF9 (CD137) and TNFSF14 protein at the NK cell surface 
(Fig 2A). TNFSF14 was induced several fold higher on the R-NK (CD107+) cells 
compared to their non-responding counterparts (CD107
neg
, NR-NK; Fig. 2A), in 
agreement with the microarray data.  In contrast, little induction of CD160 protein 
was observed.  Increased SELL gene expression (encoding L-selectin, CD62L) was 
detected in the R-NK population (Fig. 1).  However, CD62L was rapidly and 
completely removed from the cell surface of the R-NK cells (Fig. 2A), consistent with 
previous observations demonstrating protease mediated CD62L shedding upon NK 
cell activation (26). The K562 cell line was not unique in its ability to induce 
TNFSF14 expression in NK cells and several other human cell lines representing both 
hematopoietic and solid tumors preferentially induced the expression of TNFSF14 on 
tumor responding (CD107+) NK cells (Fig. S1). 
Analysis of the kinetics of TNFSF14 protein expression revealed that like 
CD69, TNFSF14 was detectable at the cell surface within one and a half hours of 
tumor cell contact.  Furthermore, both CD69 and TNFSF14 remained at the cell 
surface in response to continual stimulation (Fig. 2B). Although we detected 
TNFSF14 induction using gene expression profiling, we considered the possibility 
that the very rapid induction of TNFSF14 at the cell surface might result from the 
mobilisation of an intracellular pool of pre-existing protein.  However, stimulation of 
NK cells with K562 in the presence of actinomycin D or cycloheximide revealed that 
the induction of TNFSF14 required de novo gene expression and protein synthesis 
(Fig. 2C).  
 
TNFSF14 expression is induced by CD16 and by synergism of multiple NK cell 
activation receptors 
The rapid induction of TNFSF14 expression in NK cells in response to tumor cell 
lines suggested that the ligation of tumor-sensing NK cell activation receptors was 
coupled to TNFSF14 production. We analysed whether cross-linking of individual 
NK cell activation receptors, or combinations thereof, led to TNFSF14 expression.  
We loaded mouse P815 cells (bearing Fc receptors) with receptor-specific antibodies, 
co-cultured these antibody displaying cells with human NK cells for five hours and 
then analysed NK cell granule exocytosis and TNFSF14 expression (Fig. 3).  Modest 
induction of degranulation and TNFSF14 expression was observed via cross-linking 
of 2B4 and NKG2D, but this was greatly increased as combinations of activation 
receptors were ligated.  The exception was CD16, where ligation was sufficient to 
induce TNFSF14 expression on the majority of NK cells. These results indicate that 
TNFSF14 induction was coupled to the principal activation pathways of NK cells, 
allowing them to produce this immunomodulatory cytokine when encountering tumor 
cells or infected cells, either by natural killing mechanisms or via the engagement of 
CD16.  
 
Cytokine-mediated induction of TNFSF14 and its immunomodulatory activity 
Studies on the kinetics of the immune response to infection have shown that NK cell 
activation is an early event, but is preceded by the synthesis of type I IFN (IFN-I) and 
monocyte-derived cytokines such as IL-12 and IL-18 (27). Indeed, these cytokines 
activate NK cells by enhancing cytotoxic activity and IFN-γ production (28). 
However, neither IFN-I nor a combination of IL-12 and IL-18 was capable of 
inducing cell surface TNFSF14 expression (Fig. 4A). In contrast, IL-15, a cytokine 
produced during the early stages of innate immunity (for example, following IFN-I 
stimulation of DC; (29)) did stimulate TNFSF14 expression, as did IL-2 treatment, 
consistent with the use of common signalling chains by the IL-2 and IL-15 receptors 
(Fig. 4A). Both TNF and TNFSF14 can be released from the cell surface via 
proteolytic cleavage (30, 31) and stimulation of NK cells with PMA and ionomycin 
induced shedding of both cytokines, whereas stimulation with IL-2 or IL-15 induced 
TNFSF14 release, but little TNF (Fig. 4B).  
Co-culture of TNFSF14 transfected cells with iDC promotes DC maturation in 
a TNFSF14 dependent manner (32). The expression of TNFSF14 by NK cells and the 
importance of NK-DC interactions in the shaping of adaptive immunity (5, 33) 
suggested that NK cell derived TNFSF14 might participate in this cross-talk. 
Stimulation of immature DC (iDC; generated in vitro from CD14+ monocytes) with 
purified TNF or TNFSF14 resulted in the increased expression of CD40, CD86 and 
HLA-DR (Fig. 4C), consistent with pro-inflammatory cytokine mediated 
differentiation of iDC to a more mature, antigen-presenting phenotype (32, 34). Co-
culture of NK cells and DC induces CD86 expression on the DC (3, 4). Co-culture of 
IL-2 stimulated NK cells with iDC induced the expression of CD86 on the iDC and 
the use of blocking antibodies demonstrated that CD86 induction was dependent upon 
both TNFSF14 and TNF (Fig. 4D).  
Pro-inflammatory cytokines exert their effects on multiple cell types and like 
TNF, TNFSF14 has previously been shown to induce the expression of ICAM-1 on 
endothelial cells (35). Accordingly, IL-2 stimulated NK cells induced ICAM-1 
expression on human umbilical vein-derived endothelial cells in a TNFSF14-
dependent manner (Fig. S2) 
 
Licensed NK cells preferentially produce TNFSF14 and activate DC in response 
to tumor stimulation. 
The induction of TNFSF14 expression was confined to the tumor responsive NK cell 
population (CD107+, R-NK; Fig. 1 and 2).  This suggested that TNFSF14 expression 
might be restricted to NK cells that were functionally licensed by virtue of expressing 
inhibitory receptors reactive with self-MHC class I molecules. We determined the 
KIR ligand haplotype of donor blood samples and then analysed K562-induced 
TNFSF14 expression on NK cells from these donors according to whether the cells 
expressed KIR molecules specific for self-MHC class Ia molecules and the inhibitory 
receptor NKG2A (a receptor for the MHC class Ib molecule, HLA-E).  Tumor-
induced TNFSF14 expression was approximately ten fold-higher in the cells 
expressing NKG2A and two self reactive KIRS compared to NK cells lacking 
expression of these receptors (Fig. 5A and S3).  Indeed, NK cells expressing either 
NKG2A or a single self-reactive KIR expressed significantly more TNFSF14 in 
response to K562 stimulation than NK cells expressing neither NKG2A nor self-
reactive KIRs. Furthermore, the magnitude of TNFSF14 induction was proportional 
to the number of self-reactive KIRS and greater in the NKG2A+ compared to the 
NKG2A
neg
 population (Fig. 5B).  These results demonstrate that TNFSF14 expression 
in response to tumor target cells preferentially occurs in the licensed NK cell 
population and that both NKG2A and KIRs can license TNFSF14 production. The 
activation of NK cells with IL-2 converts functionally hyporesponsive cells lacking 
inhibitory receptors for self-MHC class I molecules (i.e. unlicensed cells) into a 
responsive subset (11, 14). Accordingly, TNFSF14 was produced by both the licensed 
and unlicensed NK cell subsets when stimulated with either IL-2 or IL-15 (Fig. S4). 
We then analysed the ability of the tumor-stimulated NK cells to mediate 
CD86 expression by iDC. We co-cultured NK cells with K562 tumor cells for four 
hours and sorted the R-NK and NR-NK cell fractions based on display of CD107 at 
the cell surface (as performed for the gene expression profiling).  These sorted 
fractions were then analysed for TNFSF14 expression; the bulk of R-NK cells were 
TNFSF14+CD107+. Importantly, although some TNFSF14 expression was detected 
in the NR-NK fraction, the level of expression of TNFSF14 at the cell surface was 
much higher in the R-NK cell population (Fig. 5C).  The sorted R-NK and NR-NK 
fractions were then co-cultured with autologous iDC for forty-eight hours in the 
presence of anti-TNFSF14 or a control antibody.  The R-NK fraction expressing 
TNFSF14 induced the expression of CD86 on almost half of the iDC in a TNFSF14-
dependent manner. In contrast, the NR-NK fraction produced little TNFSF14 and 
these NK cells did not induce CD86 expression on the co-cultured iDC (Fig. 5C and 
D). Thus, licensed NK cells, endowed with the ability to respond to target cell 
stimulation, induce the expression of TNFSF14 in response to tumor cells and these 
stimulated licensed cells induce DC expression of CD86 expression in a TNFSF14 
dependent manner following NK-DC cross-talk. 
Discussion.  
These results reveal that NK cell activation, either by tumor cells, IL-2 or IL-15 
results in the rapid production of biologically active TNFSF14, a cytokine endowed 
with potent and diverse immunomodulatory activity, including the ability to enhance 
anti-tumor immunity (36, 37). Human NK cells expressing TNFSF14 have previously 
been observed in the gut, where its expression is constitutive (38). Our results 
demonstrate its very rapid induction on peripheral blood derived NK cells in response 
to a variety of stimuli. TNFSF14 was originally described as a molecule produced by 
activated T cells that binds to HVEM (TNFRSF14), the receptor for Herpes Simplex 
Virus (HSV); TNFSF14 competes with the HSV glycoprotein D molecule for HVEM 
binding, thereby blocking HSV entry (15). This study also identified lymphotoxin-α 
as an HVEM ligand and set the stage for subsequent studies from which a complex 
web of interactions between TNFSF members and both functional and decoy 
receptors has emerged (20, 21, 25). Several functions have since been attributed to 
TNFSF14, but the precise outcome of TNFSF14/HVEM interactions are dependent 
upon the availability of other ligands and receptors in either cis or trans 
conformations that compete for interaction with one another (20, 21, 25).  
The ectopic expression of TNFSF14 at tumor sites enhances CTL responses 
(36, 37). Our results reveal that NK cells can provide the TNFSF14 upon interaction 
with tumor cells. Ligation of tumor sensing NK cell activation receptors thus 
coordinates cytotoxic granule exocytosis (leading to tumor cell destruction) with the 
production of chemokines, TNF, IFN-γ and, as shown here, the rapid expression of 
TNFSF14. Collectively, these molecules aid local responses, such as the recruitment 
of inflammatory and immune cells to the lesion, and promote the maturation of DCs 
and skewing towards Th1 responses. A role for TNF in NK cell induced DC 
maturation has been reported previously (3, 5). Our results show that TNFSF14 also 
participates in this process. Whilst TNF and TNFSF14 share certain pro-inflammatory 
activities, TNFSF14 has non-redundant functions; TNFSF14 deficient mice exhibit 
reduced migration of cells to lymph nodes during immune responses and TNFSF14 
(from a source other than T cells) is required in these animals to initiate T cell 
responses (39). TNFSF14 alone is not as potent as TNF in promoting DC maturation 
and other factors are likely required (32). The requirement for TNFSF14 in promoting 
adaptive responses varies according to the antigenic dose, with lower doses showing 
an increased dependency on this cytokine (39). Our data, together with that previously 
reported (4), shows that IL-2 stimulated NK cells make little TNF. However, IL-2 
activated NK cells produce TNF following NKp30 ligation and promote DC 
maturation in a TNF-dependent (and NKp30 dependent) manner (5). Hence, IL-2 
induces TNFSF14 directly and NKp30 ligation (by the DC) induces TNF. Both 
cytokines then induce DC maturation. Resting NK cells have been previously shown 
to induce DC maturation in a TNF dependent manner (3). However, these assays were 
performed in the absence of tumor cells and were optimal in the presence of LPS, 
suggesting that in this case, DC-derived TNF may be driving the maturation process.  
In our experiments, NK cells stimulated with tumor cells alone (without 
exogenous cytokines) produced TNFSF14, and NK-DC co-culture induced DC 
maturation in a TNFSF14 dependent manner, establishing a role for TNFSF14 and the 
HVEM axis in NK-DC cross-talk.  We co-cultured both sorted R-NK and NR-NK 
cells with iDC and only the TNFSF14 producing R-NK cells promoted DC 
maturation. Importantly, immature DC express both HVEM and TNFSF14 (32, 40) 
and we cannot formally exclude a role for DC-derived TNFSF14 in the DC 
maturation process. However, our results with NK cells support data from Morel et al, 
showing that the TNFSF14 transfected cells delivered TNFSF14-dependent (and 
HVEM-dependent) maturation signals to iDC (32), and experiments in which 
TNFSF14 supplied in the trans configuration signals through HVEM to activate NF-
κB (41). NK cells are also activated as a result of NK-DC cross-talk (4, 42, 43) and 
additional interactions between members of the HVEM regulatory network have been 
shown to activate NK cells (44). In addition, DC-derived IL-15 is of major 
importance in NK cell activation (29, 45) and the ability of IL-15 to induce TNFSF14 
production by NK cells provides a basis for the activation of both NK cells and DC 
during their interaction. Interleukin-2 is mainly produced by CD4+ cells during 
adaptive immune responses (46). The ability of IL-2 to induce TNFSF14 production 
by NK cells may simply reflect the sharing of signaling chains by the IL-2 and IL-15 
receptors. However, it is now evident that NK cell responses are not confined to the 
early stages of an immune response but are more durable, persisting into the adaptive 
phases when IL-2 is more abundant (27, 47-51).  
Our gene expression profiling identified the rapid induction of a number of 
transcripts encoding cytokines and chemokines, including GM-CSF, IFN-γ, TNF, IL-
3, IL-8 and CCL3/MIP1α.  The rapid induction of these genes (and others) can be 
attributed in part to the presence of AU-rich elements (AREs) in the 3’ untranslated 
regions that stabilise pre-existing mRNA upon cellular activation. Indeed, AREs were 
first identified in the CSF2 gene (52) and have subsequently been identified in many 
mRNAs encoding chemokines and inflammatory cytokines (53). However, the major 
TNFSF14 transcript has no readily discernible ARE and its expression was dependent 
upon new transcription, consistent with data showing induction in T cells via the 
NFAT pathway (54). With the exception of CD16, co-induction of TNFSF14 
expression and granule exocytosis required the synergistic action of multiple NK cell 
activation receptors.  This mirrors the findings of Bryceson et al, where similar 
combinations were required to induce a calcium flux, granule exocytosis and 
production of TNF and IFN-γ, with CD16 being the only single receptor sufficient to 
induce these responses (55). Such synergy is not required for all NK cell responses, 
with chemokine production requiring fewer activation signals than granule exocytosis 
or cytokine production (56). Thus, TNFSF14 more closely resembles TNF and IFN-γ 
rather than CCL3/MIP1α production in terms of its induction via cell surface 
receptors. Whether this reflects the requirement for activation-induced gene 
expression for these cytokines compared to the stabilisation of pre-existing 
chemokine transcripts is currently under test. 
Our identification of NK cell TNFSF14 expression was due to its induction in 
the R-NK cell population following tumor stimulation. The presence of R-NK and 
NR-NK populations in a single individual reflects the functional licensing of only 
those NK cells that express inhibitory receptors against self-MHC molecules (11-14). 
We were able to demonstrate that TNFSF14 protein production occurred 
preferentially in these licensed NK cells and that both KIR family and NKG2A/CD94 
receptors were involved in this process. Previous studies have shown that self-reactive 
KIRs, as well as other MHC class I receptors, notably NKG2A/CD94 and ILT2, play 
a role in functional licensing (12, 13, 19). At high NK:DC ratios, activated NK cells 
kill DC, an activity which has been suggested to allow NK cells to regulate DC 
function and the onset of adaptive immunity (3, 43). Restricting target-cell induced 
TNFSF14 production to licensed NK cells may be important in allowing the activated 
NK cell to kill the DC if required. Furthermore, restricting the expression of 
TNFSF14 to this self-MHC regulated population of NK cells clearly provides a 
safeguard against the release of this pro-inflammatory mediator in response to healthy 
tissue. The emerging evidence for a role for TNFSF14 in inflammatory disease is 
testament to the need for such regulation (57, 58). However, infection may require the 
host to maximise its responses and utilise unlicensed NK cells that are uninhibited by 
self-MHC class I molecules; pro-inflammatory cytokines have been shown to 
override the licensing mechanism and allow unlicensed cells to respond (11, 59). 
Accordingly, both licensed and unlicensed NK cells produced TNFSF14 when 
stimulated with IL-2 or IL-15. In vivo, such responses are likely to be localised to the 
lesion, thereby minimizing collateral damage. 
In summary, we have shown that human NK cell activation leads to the 
induction of TNFSF14 expression. The ability of NK cells to produce TNFSF14 
confers the potential to modulate many cell types involved in immune and 
inflammatory responses. In particular, the ability to aid DC maturation provides a key 
link between innate and adaptive immunity. The broad immunomodulatory activity of 
TNFSF14 must be efficiently regulated and restricting TNFSF14 expression to the 
licensed NK cell population provides a safeguard by which potentially damaging 
activity against healthy tissues is restricted.  
 
Materials and Methods  
 
Primary cell isolation and culture. 
Samples were collected following informed consent and ethical review by the Leeds 
Teaching Hospitals NHS Trust. Peripheral blood mononuclear cells from healthy 
donors were used to purify NK cells (by indirect selection) or monocytes (via CD14 
selection) using reagents from Miltenyi Biotec. Monocytes were cultured for five 
days in the presence of 800 U/ml GM-CSF and 400 U/ml IL-4 (R&D Systems) to 
generate immature dendritic cells (iDC). KIR and KIR ligand typing was performed 
using a KIR HLA ligand kit (from Olerup) that amplifies pertinent alleles of the 
HLA-C1, -C2, Bw4
Thr80
, Bw4
Ile80
 and HLA-A
Bw4
 groups to be identified. 
 
Gene expression analysis. 
A scaled up NK cell degranulation assay (60-62) provided the material for the 
microarray analysis. After four hours of co-culture, cells were sorted on a Beckman 
Coulter MoFlo cell sorter and responding (R) and non-responding (NR) NK cells 
purified according to the CD56
dim
CD107
neg
 and CD56
dim
CD107+ phenotype 
respectively. cDNA was synthesised from fractions pooled from three donors 
(collected from six experiments) and a separate sample from one donor (collected 
from three experiments), each sample containing approximately one million cells. 
Array analysis was performed using Illumina Sentrix HumanRef-8 v3 Beadchips and 
an Illumina BeadArray reader. The data is available from the Gene Expression 
Omnibus (ncbi.nlm.nih.gov/geo/); accession number GSE55977. For validation, R-
NK and NR-NK fractions were sorted from repeat degranulation assays and analysed 
using quantitative RT-PCR with Taqman probes (from ABI/Life Technologies). 
Samples were normalised to 18S rRNA and compared using ∆∆CT method, as 
previously described (63). 
 
TNFSF14 expression.  
TNFSF14 (and TNF) expression by responding and non-responding NK cells was 
assayed using antibodies against CD56, CD3, CD107, TNF and TNFSF14 and a BD 
Biosciences LSRII flow cytometer (details of antibody clones are provided in the 
supplementary information). Analysis was performed on NK cells treated with 
50U/ml IFN-I, 20ng/ml IL-12 plus 20ng/ml IL-18, 300U/ml of IL-2, 30ng/ml IL-15 or 
50ng/ml PMA plus 500ng/ml ionomycin (Miltenyi Biotech) for eight hours before 
analysis. All degranulation assays used an Effector:Target ratio of 1:1 with either 
tumor target cells or antibody loaded P815 cells. For the latter, P815 cells were loaded 
with combinations of anti-NK receptor antibodies (or an IgG control) at 7µg/ml for 20 
mins at room temperature and washed once before NK cell co-culture. Soluble 
cytokine was detected by ELISA using supernatants from NK cells stimulated with 
IL-2, IL-15 or PMA/ionomycin (or in media alone) for 24 hours. Supernatants were 
diluted and assayed using either a TNFSF14 ELISA (R&D Systems) or TNF ELISA 
(Peprotech).  
 
NK-DC Co-culture. 
Immature DC were prepared from monocytes (as described above) and fresh 
autologous NK cells were purified on day 5 of the iDC culture. NK cells were co-
cultured with K562 and R-NK and NR-NK fractions collected by FACS based on 
CD107 expression. These sorted NK cells were co-cultured with iDC at a 1:1 ratio for 
48 hours in either media alone or 12µg/ml of neutralizing anti-TNFSF14 antibody 
(goat polyclonal, R&D Systems), anti-TNF (goat polyclonal, R&D Systems) or 
normal goat IgG. IL-2 activated NK cells were co-cultured at an NK:DC ratio of 1:3 
for 15 hours. The IL-2 activated NK cells were co-cultured with iDC at lower 
NK:iDC rations and for less time than those used for tumor-stimulated NK cells 
because of the propensity of the more cytotoxic IL-2 activated NK cells to kill iDC 
(64). Induction of CD86 expression was analysed on the DCs in the co-culture by 
gating on CD11c
+
 cells. 
 
Further details are provided in supplementary information. 
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Figure Legends 
 
Figure 1 
Gene expression profiling of tumor stimulated human NK cells 
(A) Primary human NK cells (isolated from healthy donors) were co-cultured for 4 
hours with K562 tumor cells and the responding (R-NK) and non-responding (NR-
NK) cell populations were identified by staining for cell surface expression of CD56 
(as a marker of NK cells) and CD107 (as a marker of NK cell degranulation). The R-
NK and NR-NK populations were purified by FACS and used as a source of mRNA 
for cDNA synthesis and gene expression profiling using Illumina arrays. The inset 
shows CD107 display (x-axis) versus CD56 expression (y-axis) on NK cells in the 
absence of tumor targets. 
(B) Venn diagram of the number of genes exhibiting a significant difference in 
expression between the R-NK and NR-NK cell populations (greater than 1.5 fold 
change; P<0.05) of samples from a single donor and three pooled donors. A list of the 
541 genes differentially expressed in both the single donor and pooled donor datasets 
is provided in supplementary dataset 1. The array data is available from the Gene 
Expression Omnibus (ncbi.nlm.nih.gov/geo/); accession number GSE55977. The 
graph shows validation (using quantitative RT-PCR) of a selection of genes exhibiting 
differential expression in the array analysis (in order of increasing expression in the 
R-NK population, as determined by the array analysis). 
(C) Summary of differential expression between the R-NK and NR-NK samples. 
Selected genes exhibiting >1.5 fold upregulation (P<0.05) in the R-NK cell fraction 
are shown according to function. Genes with a defined AU rich element (ARE) in the 
3’ untranslated region (52, 53, 65, 66) are indicated (*), as are genes encoding 
molecules in the HVEM regulatory axis (**); TNFSF6 (FASL) has an ARE (67) and 
it is linked to the HVEM axis via its binding to DcR3(***). Additional details (gene 
ID, function and references) are provided in the supplementary information. 
(D) The HVEM regulatory axis. The top row indicates ligands, the middle row 
receptors. Both TNF (TNFSF2) and TNFSF14 (LIGHT) activate NF-κB. This panel is 
based on information presented in published reviews (20, 21). 
 
 
 
Figure 2 
Tumor cell stimulation of NK cells induces production of TNFSF14. 
(A) Expression of cell surface molecules detected by gene expression profiling versus 
CD107 display on unstimulated NK cells (No target) and NK cells stimulated with 
tumor cells (+K562). For the latter, the cell surface expression of molecules analysed 
on the y-axis is expressed as R/NR; the ratio of expression in the tumor responding 
(CD107+) versus non-responding (CD107
neg
) populations (based on mean 
fluorescence intensity on the y-axis; the corresponding gates are shown). This data is 
representative of three separate experiments performed. 
(B) Sustained expression of TNFSF14 (and CD69) in the continued presence of tumor 
cells. NK cells and K562 cells were co-cultured for the times indicated and cell 
surface TNFSF14 and CD69 were analysed by flow cytometry. The values indicate 
the percentage of cells in each quadrant. cAb is an isotype control antibody for the 
anti-CD69 and anti-TNFSF14 staining. This experiment is representative of three 
separate experiments performed. 
(C) Induction of TNFSF14 expression requires de novo gene expression. NK cells 
alone (no target) or NK cells co-cultured with K562 cells (+K562) were cultured for 5 
hours in the presence of 5µM actinomycin D (ActD) to inhibit transcription or 50µM 
cycloheximide (CHX) to inhibit translation (or with DMSO, the solvent for these 
compounds) and the cell surface expression of TNFSF14 and CD69 analysed by flow 
cytometry. The values indicate the percentage of cells in each quadrant. This data is 
representative of two separate experiments performed. 
 
Figure 3 
Induction of TNFSF14 by NK cell activation receptor cross-linking.   
Cell surface expression of TNFSF14 and CD107 was analysed on NK cells after co-
culture with P815 cells displaying antibodies against NK cell activation receptors. 
P815 cells were loaded with antibodies against a single receptor, or combinations of 
receptors as indicated (or without antibody, labelled Media). K562 tumor cells were 
used in place of antibody loaded P815 cells as a positive control for TNFSF14 
expression and degranulation. The values indicate the percentage of cells in the each 
quadrant. This experiment is representative of four separate experiments performed. 
 
Figure 4 
Cytokine induction of immunomodulatory TNFSF14. 
(A) Expression of TNF or TNFSF14 in response to cytokine treatment or a 
combination of PMA and ionomycin (PMA/I), as indicated. NK cells (2.5x10
5
) were 
cultured without stimulation (unstimulated) or in the presence of 50U/ml IFN-I, 
20ng/ml IL-12 and IL-18, 300U/ml of IL-2, 30ng/ml IL-15, or 50ng/ml PMA plus 
500ng/ml ionomycin (PMA/I) for eight hours. Cells were stained for cell surface 
TNFSF14 expression or processed for intracellular staining for TNF. The values 
indicate the percentage of expressing cells. This data is representative of three donors 
for TNF and six donors for TNFSF14. 
(B) Release of soluble TNF or TNFSF14 by IL-2, IL-15 or PMA/I treated NK cells. 
NK cells (2.5x10
5
) were stimulated with the treatments shown in panel A for twenty 
four hours and the supernatants analysed for TNF or TNFSF14 by ELISA (performed 
using at least three different donors). Media is the culture media without any added 
cells as a background control. 
(C) Maturation of DC in response to recombinant TNFSF14. Immature (i) DC 
(differentiated from CD14+ monocytes) were left untreated or treated with 
recombinant TNF or TNFSF14 (100ng/ml of each) for 24 hours and analysed for cell 
surface markers of DC maturation, CD86, CD40 and HLA-DR using flow cytometry.  
(D) Left panel; 1x10
5 
IL-2 stimulated NK cells were applied to 3x10
5 
iDC for 15 
hours in the presence of antibodies against TNFSF14 or TNF or both cytokines (or a 
control antibody, cAb). The induction of CD86 on the iDC was analysed by flow 
cytometry, the percentage of cells expressing CD86 is shown for each treatment.  The 
right panel summarises the data collected from five donors. Expression of CD86 on 
the DC co-cultured with IL-2 stimulated NK cells in the presence of a control 
antibody (cAb) was assigned an expression level of 1. The reduction in expression of 
CD86 in the presence of the different anti-cytokine antibodies is indicated; P<0.05* 
and P<0.005**, as determined by the paired Student’s T test. 
 
Figure 5 
TNFSF14 is produced by functionally licensed NK cells. 
Five donors were typed for KIR ligands and self-KIR molecules as well as NKG2A 
expression by flow cytometry. NK cells from these donors were then co-cultured with 
K562 cells for six hours and cell surface TNFSF14 expression was analysed on NK 
cells expressing none of these receptors, individual receptors or combinations thereof 
(see Fig. S3 and supplementary information for details of the gating strategy). (A) Cell 
surface TNFSF14 expression on NK cells expressing no detectable NKG2A or self-
reactive KIRs versus NK cells expressing NKG2A and two self-reactive KIR 
molecules. The difference in TNFSF14 between these unlicensed and licensed NK 
cells is approximately ten-fold based on the mean fluorescence intensity of TNFSF14 
expression. (B) Cell surface expression of TNFSF14 in response to tumor cell 
stimulation on NK cells expressing none (0 KIR), one (1KIR) or two self-reactive 
KIRs (2KIR) with or without NKG2A expression. The data show that any one of the 
inhibitory receptors (either NKG2A or KIR) confers a statistically significant effect 
on TNFSF14 expression (P<0.05*, P<0.005** as determined by a two tailed 
Student’s T test). (C) Tumor stimulated NK cells induce CD86 expression on iDC in a 
TNFSF14 dependent manner. NK cells were co-cultured with K562 tumor cells for 
four hours and the R-NK and NR-NK cells isolated by FACS based on CD107 
display alone. Samples from these sorted populations were reanalysed for expression 
of cell surface TNFSF14 and CD107 molecules (centre panel; Post-sort NK) and the 
remaining cells co-cultured with iDC (for forty eight hours at a ratio of 1:1) in the 
presence or absence of 10µg/ml of anti-TNFSF14 antibody or a control antibody 
(cAb). CD86 expression of the iDC was analysed by flow cytometry and the 
percentage of CD86 expressing cells with the different treatments is shown. The top 
panel of the iDC analysis shows iDC plus control antibody (cAb), without added NK 
cells. (D) Induction of cell surface CD86 expression on iDC following co-culture with 
NR-NK or R-NK cells in the presence of either a control Ab (cAb) or anti-TNFSF14 
antibody. This data is the fold change in mean fluorescence intensity of CD86 
expression from three independent experiments (P<0.05*, P<0.005**, as determined 
by a two tailed Student’s T test). 
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